# Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies

> **NCT07345728** · NA · RECRUITING · sponsor: **Donghua Zhang** · enrollment: 28 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Malignancies

## Interventions

- **DRUG:** Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies

## Key facts

- **NCT ID:** NCT07345728
- **Lead sponsor:** Donghua Zhang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2029-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07345728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07345728, "Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07345728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*